AMY-101 acetate|CAS 0|DC Chemicals

Cas No.:
Chemical Name:	AMY-101 acetate
Synonyms:	YICV-{Trp(Me)}-QDW-{Sar}-AHRC-{N(Me)Ile}-NH2 (Disulfide bridge:Cys3-Cys13)
Formula:	C₈₅H₁₂₁N₂₃O₂₀S₂
M.Wt:	1849.16
Sotrage:	Protect from lightPowder-80°C2 years-20°C1 year*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Cat. No.	Product name	Field of application
DC47298	Lipoteichoic acid	Lipoteichoic acid, a cell wall component of Staphylococcus aureus, activates the complement system via C3 induction and CD55 inhibition.
DC47058	Vemircopan	Vemircopan is a complement factor D inhibitor.
DC46608	Compstatin control peptide TFA	Compstatin control peptide TFA is a complement inhibitor that binds and inhibits cleavage of complement C3.
DC45525	POT-4 TFA	POT-4 TFA (AL-78898A TFA), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. POT-4 TFA can be used for age-related macular degeneration research.
DC45303	POT-4	POT-4 (AL-78898A), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. POT-4 can be used for age-related macular degeneration research
DC44839	Compstatin control peptide	Compstatin control peptide is a complement inhibitor that binds and inhibits cleavage of complement C3.
DC43963	FD-IN-1	FD-IN-1 (Compound 12) is an orally bioavailable and selective factor D (FD) inhibitor with an IC50 of 12 nM. Complement FD, a highly specific S1 serine protease, plays a central role in the alternative complement pathway of the innate immune system. FD-IN
DC41847	AMY-101 acetate	AMY-101 acetate (Cp40 acetate), a peptidic inhibitor of the central complement component C3 (KD = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 acetate (Cp40 acetate) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation.
DC41798	TLQP-21 TFA	TLQP-21 TFA, a VGF-derived peptide endowed of endocrine and extraendocrine properties, is a potent G-protein-coupled receptor complement-3a receptor1 (C3aR1) agonist (EC50: mouse TLQP-21=10.3 μM; human TLQP-21=68.8μM). TLQP-21 TFA activates C3aR1 to induce an increase of intracellular Ca2+. TLQP-21 TFA is used for the research in regulation of nociception and other relevant physiologic functions.
DC41797	TLQP-21	TLQP-21, a VGF-derived peptide endowed of endocrine and extraendocrine properties, is a potent G-protein-coupled receptor complement-3a receptor 1 (C3aR1) agonist (EC50: mouse TLQP-21=10.3 μM; human TLQP-21=68.8 μM). TLQP-21 activates C3aR1 to induce an increase of intracellular Ca2+. TLQP-21 is used for the research in regulation of nociception and other relevant physiologic functions.